Sangamo Therapeutics (Sangamo Therapeutics) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Apr. 27, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Sangamo Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Sangamo Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Sangamo Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangamo Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Sangamo Therapeutics (NAS:SGMO) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Sangamo Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

GBY:Germany

Address

7000 Marina Boulevard, Brisbane, CA, USA, 94005

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Executives

Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney	director	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow	officer: SVP-Chief Development Officer	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker	director
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby	officer: SVP, Gen. Counsel & Secretary	7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb	officer: EVP & General Counsel	5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot	officer: SVP, Chief Scientific Officer	7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott	officer: SVP, Head of Development	7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier	officer: EVP, Technical Operations	7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung	officer: EVP Chief Business Officer	7000 MARINA BLVD, BRISBANE CA 94005